Plasma phospholipid transfer protein (PLTP) plays a key role in lipid and lipoprotein metabolism. Known? functions of PLTP include transfer of phospholipids (PL) and cholesterol among lipoproteins and between? lipoproteins and cells, modulation of HDL level, size, and composition, and enhancement of cellular? cholesterol efflux. Current data indicate that most PLTP in human plasma associates with distinct HDL? particles and lacks the ability to transfer PL from liposomes to HDL in vitro. The physiological significance? of this inactive form of PLTP is unknown. We recently found that PLTP interacts with cell surface ABCA1? and promotes transport of cell cholesterol and PL to HDL particles. The structural domains of PLTP and? ABCA1 involved in this process remain to be determined. The major goals of this proposal are to establish? the structural basis and the metabolic and pathologic relevance of inactive PLTP, and to define the interaction? of PLTP with cellular ABCA1 and its role in reverse cholesterol transport. Our overall hypothesis is that? specific structural features of PLTP are critical for lipid transport and for interacting with ABCA1. To test? this hypothesis, we will determine the biochemical characteristics of lipoprotein particles containing active? and inactive PLTP, delineate their potential molecular differences, examine the possibility of their? interconversion, and study their roles in modulating plasma lipoproteins and in cellular lipid homeostasis. We? will also characterize the mechanisms of PLTP-mediated lipid removal by the ABCA1 pathway, and define? molecular properties of PLTP and ABCA1 required for their interaction and lipid efflux using PLTP domainspecific? peptides, and PLTP and ABCA1 mutants. Furthermore, we will investigate the pathological? relevance of the balance between active and inactive PLTP in the pathogenesis of FCHL and the quantitative? trait loci for PLTP activity and active and inactive PLTP mass in families with FCHL in collaboration with? Project 1. The proposed studies should provide novel insights into the mechanisms of action and the role of? PLTP in lipoprotein metabolism and pathophysiology. A better understanding of the basic function and? mechanisms of action of PLTP could lead to more targeted treatment and prevention of lipoprotein disorders? that contribute to the development of cardiovascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL030086-22
Application #
7551422
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
22
Fiscal Year
2006
Total Cost
$362,620
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Zhang, Meng; Zhai, Xiaobo; Li, Jinping et al. (2018) Structural basis of the lipid transfer mechanism of phospholipid transfer protein (PLTP). Biochim Biophys Acta Mol Cell Biol Lipids 1863:1082-1094
Zhao, Xue-Qiao; Phan, Binh An P; Davis, Joseph et al. (2016) Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol 10:1091-7
Monette, Jeffrey S; Hutchins, Patrick M; Ronsein, Graziella E et al. (2016) Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration. Circ Res 119:83-90
Deguchi, Hiroshi; Wolfbauer, Gertrud; Cheung, Marian C et al. (2015) Inhibition of thrombin generation in human plasma by phospholipid transfer protein. Thromb J 13:24
Rosenthal, Elisabeth; Blue, Elizabeth; Jarvik, Gail P (2015) Next-generation gene discovery for variants of large impact on lipid traits. Curr Opin Lipidol 26:114-9
Wight, Thomas N; Kang, Inkyung; Merrilees, Mervyn J (2014) Versican and the control of inflammation. Matrix Biol 35:152-61
Shao, Baohai; Tang, Chongren; Sinha, Abhishek et al. (2014) Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res 114:1733-42
Wight, Thomas N; Kinsella, Michael G; Evanko, Stephen P et al. (2014) Versican and the regulation of cell phenotype in disease. Biochim Biophys Acta 1840:2441-51
Zambon, Alberto; Zhao, Xue-Qiao; Brown, B Greg et al. (2014) Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol 113:1494-8
Phan, Binh An P; Moore, Andrew B; Davis, Joseph et al. (2014) Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). J Clin Lipidol 8:489-93

Showing the most recent 10 out of 485 publications